Office of New Drugs director returns
Executive Summary
FDA Office of New Drugs Director John Jenkins returns to his position at the agency following a personal leave. OND Deputy Director Sandra Kweder served as acting director during Jenkins' absence. Kweder represented the office on the decision to request a "black box" warning on antidepressant labeling and testified on behalf of FDA at the Senate Finance Committee's hearing on the Vioxx withdrawal (1"The Pink Sheet" Oct. 18, 2004, p. 3). Jenkins represented OND on a Dec. 17 conference call on Celebrex safety data...
You may also be interested in...
Antidepressant “Black Box” Presents Barrier To DTC Advertising
FDA's proposed "black box" warning for all antidepressants would likely mean an end to television ads for the products
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.